HC Wainwright Analysts Lower Earnings Estimates for ANRO

Key Points

• HC Wainwright lowered Alto Neuroscience’s Q3 2026 EPS estimate to a loss of $0.68 from $0.67, while maintaining a Buy rating and $60 price target.
• Analysts expect continued losses, including a projected $2.82 loss per share for fiscal 2026 versus the $2.68 consensus estimate; however, the broader analyst consensus remains Moderate Buy with a $37.88 target price.
• Alto Neuroscience shares were reported up 7.3% and recently traded near $24.48. The company’s latest quarterly loss of $0.65 per share beat expectations for a $0.73 loss.

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of Alto Neuroscience in a research note issued to investors on Monday, October 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.68) for the quarter, down from their prior forecast of ($0.67). HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Alto Neuroscience's Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($2.82) EPS, Q1 2027 earnings at ($0.76) EPS, Q2 2027 earnings at ($0.79) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.80) EPS, FY2027 earnings at ($3.17) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.01) EPS and FY2030 earnings at ($3.51) EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Zacks Research raised Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 20th. Wall Street Zen downgraded shares of Alto Neuroscience from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. BTIG Research raised their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, August 13th. Finally, Wedbush boosted their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.88.

Alto Neuroscience Trading Up 7.3%

NYSE ANRO opened at $24.48 on Wednesday. Alto Neuroscience has a twelve month low of $9.73 and a twelve month high of $37.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock has a market cap of $960.64 million, a price-to-earnings ratio of -10.12 and a beta of 1.31. The firm's 50 day moving average price is $29.98 and its two-hundred day moving average price is $26.32.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.08.

Hedge Funds Weigh In On Alto Neuroscience

Large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its position in Alto Neuroscience by 48,581.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company's stock valued at $137,000 after buying an additional 5,344 shares during the last quarter. GK Wealth Management LLC acquired a new stake in shares of Alto Neuroscience in the 2nd quarter valued at $226,000. Revisor Wealth Management LLC bought a new stake in shares of Alto Neuroscience during the first quarter worth $385,000. The Manufacturers Life Insurance Company bought a new stake in shares of Alto Neuroscience during the first quarter worth $534,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Alto Neuroscience during the first quarter worth $538,000.

Insiders Place Their Bets

In other Alto Neuroscience news, CFO Nicholas Smith sold 24,056 shares of the firm's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the completion of the sale, the chief financial officer owned 24,060 shares in the company, valued at approximately $621,229.20. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.25% of the company's stock.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright raised its price target on Alto Neuroscience (ANRO) to $60 from $55 while maintaining its Buy rating, signaling increased confidence in the company’s outlook. HC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy Rating
• Positive Sentiment: The analyst raised EPS forecasts for 2027, including Q1 to $(0.76) from $(0.93), Q2 to $(0.79) from $(0.97), Q3 to $(0.82) from $(1.00), and Q4 to $(0.80) from $(0.96). The full-year 2027 estimate also improved to $(3.17) from $(3.87), suggesting expectations for narrower losses.
• Positive Sentiment: HC Wainwright lifted its FY2028 EPS forecast to $(4.00) from $(4.39), another indication that projected losses may be less severe than previously expected. Alto Neuroscience Stock Gets Price Target Boost from HC Wainwright
• Neutral Sentiment: The revisions remain forecasts rather than reported results. HC Wainwright still expects Alto Neuroscience to post losses, including $(2.82) EPS for fiscal 2026, compared with the current consensus estimate of $(2.68).
• Negative Sentiment: Longer-term estimates were reduced for FY2029, to $(4.01) from $(3.25), and FY2030, to $(3.51) from $(1.29). These cuts highlight continued uncertainty surrounding the company’s path to profitability, despite the unchanged Buy rating.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto's pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.